SE9402370D0 - Use of IGF-I - Google Patents

Use of IGF-I

Info

Publication number
SE9402370D0
SE9402370D0 SE9402370A SE9402370A SE9402370D0 SE 9402370 D0 SE9402370 D0 SE 9402370D0 SE 9402370 A SE9402370 A SE 9402370A SE 9402370 A SE9402370 A SE 9402370A SE 9402370 D0 SE9402370 D0 SE 9402370D0
Authority
SE
Sweden
Prior art keywords
diabetes
subject
high risk
igf
occurrence
Prior art date
Application number
SE9402370A
Other languages
English (en)
Swedish (sv)
Inventor
Charles Thivolet
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402370A priority Critical patent/SE9402370D0/xx
Publication of SE9402370D0 publication Critical patent/SE9402370D0/xx
Priority to JP8503824A priority patent/JPH10502367A/ja
Priority to US08/750,733 priority patent/US6342227B1/en
Priority to AT95925202T priority patent/ATE223729T1/de
Priority to AU29407/95A priority patent/AU689922B2/en
Priority to DE69528168T priority patent/DE69528168T2/de
Priority to PCT/SE1995/000776 priority patent/WO1996001124A1/en
Priority to EP95925202A priority patent/EP0759776B1/de
Priority to CA002194403A priority patent/CA2194403A1/en
Priority to IL11434395A priority patent/IL114343A0/xx
Priority to US10/050,298 priority patent/US20020132772A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9402370A 1994-07-04 1994-07-04 Use of IGF-I SE9402370D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I
CA002194403A CA2194403A1 (en) 1994-07-04 1995-06-22 Use of igf-i or analogues thereof in the prevention of diabetes
AU29407/95A AU689922B2 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
US08/750,733 US6342227B1 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
AT95925202T ATE223729T1 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
JP8503824A JPH10502367A (ja) 1994-07-04 1995-06-22 糖尿病を予防するためのｉｇｆ−ｉ又はその類似体の使用
DE69528168T DE69528168T2 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
PCT/SE1995/000776 WO1996001124A1 (en) 1994-07-04 1995-06-22 Use of igf-i or analogues thereof in the prevention of diabetes
EP95925202A EP0759776B1 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
IL11434395A IL114343A0 (en) 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes
US10/050,298 US20020132772A1 (en) 1994-07-04 2002-01-16 Use of IGF-I or analogues thereof in the prevention of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Publications (1)

Publication Number Publication Date
SE9402370D0 true SE9402370D0 (sv) 1994-07-04

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Country Status (10)

Country Link
US (2) US6342227B1 (de)
EP (1) EP0759776B1 (de)
JP (1) JPH10502367A (de)
AT (1) ATE223729T1 (de)
AU (1) AU689922B2 (de)
CA (1) CA2194403A1 (de)
DE (1) DE69528168T2 (de)
IL (1) IL114343A0 (de)
SE (1) SE9402370D0 (de)
WO (1) WO1996001124A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
EP1772464B1 (de) 2001-02-09 2009-08-12 Genentech, Inc. Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2011004051A1 (es) 2009-07-10 2011-01-13 Universidad Autónoma De Barcelona Composiciones de terapia génica para prevenir y/o tratar enfermedades autoinmunes
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
DE69528168T2 (de) 2003-01-09
AU2940795A (en) 1996-01-25
EP0759776A1 (de) 1997-03-05
IL114343A0 (en) 1995-10-31
DE69528168D1 (de) 2002-10-17
JPH10502367A (ja) 1998-03-03
US20020132772A1 (en) 2002-09-19
ATE223729T1 (de) 2002-09-15
EP0759776B1 (de) 2002-09-11
US6342227B1 (en) 2002-01-29
AU689922B2 (en) 1998-04-09
CA2194403A1 (en) 1996-01-18
WO1996001124A1 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
ATE31243T1 (de) Verwendung von 4-aminosalicylsaeure als entzuendungshemmender wirkstoff.
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
DE69723230D1 (de) Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
NO854182L (no) Feste med flere frihetsgrader.
SE9402370D0 (sv) Use of IGF-I
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE68925615T2 (de) Digitalrechnersystem mit Niederstromverbrauchmodus
DE3684542D1 (de) Acylcarnitine als absorptionsbeschleuniger fuer die wirkstoffverabreichung ueber die schleimhaeute der nasen-, mund-, sublingual- und vaginalhoehle.
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
IT7928417A0 (it) Composizioni farmaceutiche con esaltazione dell'attivita'terapeutica di cortisonici.
JPS5388761A (en) Electronic watch with auxiliary battery
IT8022925A0 (it) Composizioni di gomma siliconica ad un componente, vulcanizzabili atemperatura ambiente e stabili all'immagazzinamento.
IT8348747A0 (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
DE3170587D1 (en) The use of peptides as medicaments and certain novel peptides
IT8321461A0 (it) Ammidine ad attivita' farmaceutica e relativo procedimento di fabbricazione.
DK472584A (da) Mikroindkapslet medikament i konfekturematrix
IT8419681A0 (it) Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
DK399985A (da) 6-substituerede mitomycin-analoge, deres anvendelse inden for medicinen og kompositioner indeholdende forbindelserne
IT8322568A0 (it) Resina per lenti di elevata rifrattivita' e lenti prodotte con la resina stessa.
JPS52114322A (en) Photographic lens
DK146785D0 (da) Pharmaceutisk praeparat med indhold af 9alfa, 11beta-dichlor-16alfa-methyl-21-oxycarbonyldicyclohexylmethyloxypregna-1,4-dien-3,20-dion
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
IT8621394A0 (it) Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
ROSENTHAL Biological and medical research: Low level radiation, carcinogenesis, toxicology, human protein index, biophysics[Annual Technical Report]